Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

BACKGROUND: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric cancer population. Survival among metastatic RMS patients has remained dismal yet unimproved for years. We previously identified the class I-specific histone deacetylase inhibitor, entinostat (ENT), as a pharm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Skelet Muscle
Main Authors: Bharathy, Narendra, Berlow, Noah E., Wang, Eric, Abraham, Jinu, Settelmeyer, Teagan P., Hooper, Jody E., Svalina, Matthew N., Bajwa, Zia, Goros, Martin W., Hernandez, Brian S., Wolff, Johannes E., Pal, Ranadip, Davies, Angela M., Ashok, Arya, Bushby, Darnell, Mancini, Maria, Noakes, Christopher, Goodwin, Neal C., Ordentlich, Peter, Keck, James, Hawkins, Douglas S., Rudzinski, Erin R., Mansoor, Atiya, Perkins, Theodore J., Vakoc, Christopher R., Michalek, Joel E., Keller, Charles
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6528217/
https://ncbi.nlm.nih.gov/pubmed/31113472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13395-019-0198-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados